Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
Add more filters










Publication year range
1.
Hematol J ; 2(2): 97-102, 2001.
Article in English | MEDLINE | ID: mdl-11424001

ABSTRACT

INTRODUCTION: All trans retinoic acid, the active metabolite of vitamin A, exerts profound effects on cell differentiation. On normal myeloid progenitors, retinoids switch the differentiation program of granulo-macrophagic progenitors towards the granulocytic lineage and consequently reduce CFU-M colony formation. Bone marrow and peripheral blood mononuclear cells from children with Juvenile Chronic Myelomonocytic Leukaemia show typical spontaneous monocytic growth. We questioned whether in this disease, retinoids could switch myelomonocytic growth and inhibit the abnormal CFU-M colony proliferation. METHODS: Ten JCML samples were studied in the presence of ATRA in methyl cellulose colony assay, before (CFU-C) or after (pre-CFU) liquid suspension culture. RESULTS: In vitro characteristics of JCML such as spontaneous monocytic growth in the absence of growth factor was noted in all patients. In the presence of leucocyte-conditioned medium, nine samples showed only CFU-M growth and one sample CFU-GM growth. Incubation with ATRA inhibited CFU-M colony formation in nine cases. Enhancement of granulocytic differentiation (CFU-G) was noted in nine cases. ATRA also inhibited CD34+ JCML monocytic growth and GM-CSF hypersensitivity. CONCLUSION: These data suggest that, in JCML progenitors, retinoid pathways are functional and inhibition of immature monocytic progenitors cells may be achieved with retinoids, without impeding granulocytic cell growth.


Subject(s)
Antineoplastic Agents/pharmacology , Granulocyte Precursor Cells/pathology , Leukemia, Myelomonocytic, Chronic/physiopathology , Tretinoin/pharmacology , Cell Differentiation/drug effects , Cell Proliferation/drug effects , Child , Female , Granulocyte Precursor Cells/metabolism , Humans , Leukemia, Myelomonocytic, Chronic/drug therapy , Leukemia, Myelomonocytic, Chronic/pathology , Male , Tumor Cells, Cultured
2.
J Bacteriol ; 182(19): 5381-90, 2000 Oct.
Article in English | MEDLINE | ID: mdl-10986240

ABSTRACT

The extent and nature of DNA polymorphism in the mutS-rpoS region of the Escherichia coli genome were assessed in 21 strains of enteropathogenic E. coli (EPEC) and enterohemorrhagic E. coli (EHEC) and in 6 strains originally isolated from natural populations. The intervening region between mutS and rpoS was amplified by long-range PCR, and the resulting amplicons varied substantially in length (7.8 to 14.2 kb) among pathogenic groups. Restriction maps based on five enzymes and sequence analysis showed that strains of the EPEC 1, EPEC 2, and EHEC 2 groups have a long mutS-rpoS region composed of a approximately 6.0-kb DNA segment found in strain K-12 and a novel DNA segment ( approximately 2.9 kb) located at the 3' end of rpoS. The novel segment contains three genes (yclC, pad1, and slyA) that occur in E. coli O157:H7 and related strains but are not found in K-12 or members of the ECOR group A. Phylogenetic analysis of the common sequences indicates that the long intergenic region is ancestral and at least two separate deletion events gave rise to the shorter regions characteristic of the E. coli O157:H7 and K-12 lineages.


Subject(s)
Adenosine Triphosphatases , Bacterial Proteins/genetics , Conserved Sequence , DNA-Binding Proteins , Escherichia coli Proteins , Escherichia coli/genetics , Genes, Bacterial , Sigma Factor/genetics , Amino Acid Sequence , Base Sequence , DNA, Bacterial , Genome, Bacterial , Molecular Sequence Data , MutS DNA Mismatch-Binding Protein , Polymorphism, Genetic , Sequence Analysis, DNA
3.
Nature ; 406(6791): 64-7, 2000 Jul 06.
Article in English | MEDLINE | ID: mdl-10894541

ABSTRACT

The mechanisms underlying the evolution and emergence of new bacterial pathogens are not well understood. To elucidate the evolution of pathogenic Escherichia coli strains, here we sequenced seven housekeeping genes to build a phylogenetic tree and trace the history of the acquisition of virulence genes. Compatibility analysis indicates that more than 70% of the informative sites agree with a single phylogeny, suggesting that recombination has not completely obscured the remnants of ancestral chromosomes. On the basis of the rate of synonymous substitution for E. coli and Salmonella enterica (4.7 x 10(-9) per site per year), the radiation of clones began about 9 million years ago and the highly virulent pathogen responsible for epidemics of food poisoning, E. coli O157:H7, separated from a common ancestor of E. coli K-12 as long as 4.5 million years ago. Phylogenetic analysis reveals that old lineages of E. coli have acquired the same virulence factors in parallel, including a pathogenicity island involved in intestinal adhesion, a plasmid-borne haemolysin, and phage-encoded Shiga toxins. Such parallel evolution indicates that natural selection has favoured an ordered acquisition of genes and the progressive build-up of molecular mechanisms that increase virulence.


Subject(s)
Escherichia coli/pathogenicity , Evolution, Molecular , DNA, Bacterial , Escherichia coli/classification , Escherichia coli/genetics , Escherichia coli O157/genetics , Escherichia coli O157/pathogenicity , Genes, Bacterial , Phylogeny , Polymorphism, Genetic , Salmonella enterica/genetics , Virulence/genetics
4.
Epidemiol Infect ; 122(2): 329-36, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10355800

ABSTRACT

The objectives of this study were to investigate the coagulase gene polymorphism of Staphylococcus aureus isolates obtained from bovine mastitic milk and to determine the resistance of predominant and rare coagulase genotypes to bovine blood neutrophil bactericidal activities. A total of 453 isolates were collected from four countries: the Czech Republic, France, Korea and the United States. The isolates were subtyped into 40 types by restriction fragment length polymorphism (RFLP) of the coagulase gene. Twenty-three strains from predominant and rare genotypes were evaluated for their ability to resist neutrophil bactericidal activities. There were significant (P < 0.01) differences in the average percent neutrophil killing of the predominant (16.7%) and rare (39.7%) genotypes when bacteria were opsonized with antiserum. The results indicate that the profiles of coagulase genotype differ among geographic locations, and only a few genotypes prevail in each location. In addition, the predominant genotypes were more resistant to neutrophil bactericidal activities than rare genotypes.


Subject(s)
Coagulase/genetics , Mastitis, Bovine/microbiology , Milk/microbiology , Polymorphism, Genetic , Staphylococcal Infections/veterinary , Staphylococcus aureus/genetics , Animals , Bacterial Typing Techniques , Blood Bactericidal Activity , Cattle , Dairying , Female , Neutrophils/immunology , Polymorphism, Restriction Fragment Length , Staphylococcal Infections/microbiology , Staphylococcus aureus/enzymology , Staphylococcus aureus/immunology , Staphylococcus aureus/isolation & purification
5.
Eur Cytokine Netw ; 9(1): 57-60, 1998 Mar.
Article in English | MEDLINE | ID: mdl-9613678

ABSTRACT

It has previously been demonstrated that the overproduction of interleukin-6 (IL-6) is a key element in the clinical and biological abnormalities encountered in Castleman's disease (CD). The particular case of a male child with a localized form of CD is reported. In this patient, evidence was found of a correlation between systemic manifestations and circulating IL-6, and IL-6 gene overexpression in the germinal centers of hyperplastic lymph nodes. Circulating IL-6 levels were 10- to 100-fold higher than in all CD cases previously documented. This unique biological feature was closely associated with high levels of circulating IL-1 and tumor necrosis factor-alpha (TNF-alpha), which are known for their ability to induce and/or amplify IL-6 production. One month after surgical removal of the pathological lymph node, the clinical and biological abnormalities diminished, while circulating IL-6 levels dropped dramatically eight months later. It is worth noting that after resection, the time-course of the IL-6 decrease closely correlated with that of IL-1 and TNF-alpha. Considering that in various inflammatory diseases IL-1, TNF-alpha and IL-6 may act in a synergistic manner in inducing systemic manifestations, this case report raises new questions as to the nature of the systemic pathogenicity of cytokines in CD.


Subject(s)
Castleman Disease/blood , Inflammation , Castleman Disease/etiology , Castleman Disease/surgery , Child, Preschool , Cytokines/blood , Humans , Inflammation/blood , Inflammation/etiology , Inflammation/surgery , Interleukin-1/blood , Interleukin-6/blood , Male , Tumor Necrosis Factor-alpha/metabolism
6.
J Dairy Sci ; 80(9): 2025-34, 1997 Sep.
Article in English | MEDLINE | ID: mdl-9313144

ABSTRACT

The ability of Staphylococcus aureus alpha-toxin to recruit neutrophils in the milk of vaccinated cows and the bactericidal efficiency of these neutrophils were evaluated. Six lactating Holstein cows that were free of intramammary infection received systemic immunization by subcutaneous injection of Freund's incomplete adjuvant with alpha-toxin (n = 2), alpha-toxin mixed with type 5 capsular polysaccharide (n = 2), or a conjugate of these two antigens (n = 2). Controls (n = 4) and vaccinated cows (n = 6) received intramammary infusions of alpha-toxin. No increase in somatic cell count was recorded in quarter milk samples from unimmunized cows; however, 10 micrograms of alpha-toxin induced a local inflammatory reaction in vaccinated cows that was characterized by early and massive cellular recruitment into the mammary gland. More than 90% of the recruited cells were neutrophils. The speed and magnitude of the cellular recruitment were dose-dependent; the threshold dose was 0.6 microgram. Milk samples showed significant bactericidal activity against the type 5 S. aureus strain, regardless of the vaccine used, and showed a decrease in bacterial count of about 2 log10 from the initial inoculum. The best efficiency was recorded during the early phase of cellular recruitment with concomitant activation of blood-derived neutrophils. This study demonstrates that a bacterial virulence factor, alpha-toxin, is able to induce immune recruitment of neutrophils for efficient bactericidal activity in milk when cows are immunized with alpha-toxin that is used either as a nonconjugate vaccinate or as a carrier protein in a conjugate vaccine. The study also suggests that neutrophils that are recruited from blood are activated during inflammation in response to specific antigens.


Subject(s)
Bacterial Toxins/immunology , Bacterial Vaccines/immunology , Cattle/immunology , Hemolysin Proteins/immunology , Milk/immunology , Milk/microbiology , Neutrophils/immunology , Animals , Antibodies, Bacterial/blood , Antibodies, Bacterial/metabolism , Female , Immunization , Kinetics , Mammary Glands, Animal/immunology , Mammary Glands, Animal/microbiology , Milk/cytology , Serum Albumin, Bovine/metabolism
7.
Infect Immun ; 63(4): 1380-6, 1995 Apr.
Article in English | MEDLINE | ID: mdl-7890398

ABSTRACT

In order to examine the possible implication of capsular polysaccharide (CP) types 5 and 8 (CP5 and CP8) from Staphylococcus aureus in the pathological mechanism associated with staphylococcal infections, we tested the immunomodulatory effects of CP5 and CP8 on human epithelial KB cells, endothelial cells, and monocytes. Using biotinylated CP5 and CP8, we provide evidence that both CPs bind to KB cells, endothelial cells, and monocytes in a dose- and calcium-dependent manner through specific interactions. These results were confirmed by competition experiments using soluble cell extracts. Furthermore, we show that CPs bind to identical cell membrane receptors on all three types of human cells and that human normal serum contains a factor(s) which inhibits the binding of both CPs to human KB cells, endothelial cells, and monocytes. The ability of CP5 and CP8 to stimulate the production of cytokines by the human cells was then examined. CP5 and CP8 trigger KB cells to produce interleukin-8 (IL-8); endothelial cells to produce IL-8 and IL-6; and monocytes to produce IL-8, IL-6, IL-1 beta, and tumor necrosis factor alpha. The release of cytokines by all three types of cells is time dependent and dose dependent, and the tumor necrosis factor alpha production by monocytes is not affected by the addition of polymyxin B. We further confirm that human normal serum inhibits the immunomodulatory effects of both polysaccharides on each kind of cell. These results confirm that S. aureus CPs act as bacterial adhesins having immunomodulatory effects for human cells.


Subject(s)
Bacterial Adhesion , Bacterial Capsules/metabolism , Cytokines/metabolism , Endothelium, Vascular/microbiology , Epithelium/microbiology , Monocytes/microbiology , Polysaccharides, Bacterial/metabolism , Staphylococcus aureus/pathogenicity , Cells, Cultured , Humans , In Vitro Techniques , Interleukin-1/metabolism , Interleukin-6/metabolism , Interleukin-8/metabolism , Tumor Necrosis Factor-alpha/metabolism
8.
Hum Mol Genet ; 3(12): 2093-102, 1994 Dec.
Article in English | MEDLINE | ID: mdl-7881405

ABSTRACT

We have investigated the distribution of DNA methylation in chromosomes and nuclei of normal individuals and ICF (Immunodeficiency, Centromeric instability and Facial abnormalities) syndrome patients, using 5-methylcytosine monoclonal antibody. In this syndrome, DNA digestion with methyl-sensitive enzymes has previously shown a specific hypomethylation of classical satellites located in constitutive heterochromatin. The chromosome methylation pattern confirms this hypomethylation showing in addition a clear undermethylation of facultative heterochromatin (X inactive chromosome). Antibodies give, in normal and ICF chromosomes, a non-uniform labeling of euchromatin, generating a weak R-like banding pattern on chromosomes. This pattern reflects an unequal distribution of DNA methylation over the genome disclosing another aspect of chromosome organization. The breakpoints of chromosome rearrangements and the heterochromatin stretchings observed in ICF patients were analyzed by means of in situ hybridization. These chromosome modifications involve hypomethylated classical DNA satellite sequences. The underlying hypomethylation, associated with an abnormal chromatin organization, may predispose to chromosome instability.


Subject(s)
Abnormalities, Multiple/genetics , Chromosome Aberrations/genetics , Cytosine/analogs & derivatives , Face/abnormalities , Heterochromatin/metabolism , Immunologic Deficiency Syndromes/genetics , X Chromosome , 5-Methylcytosine , Abnormalities, Multiple/metabolism , Base Sequence , Case-Control Studies , Centromere , Child , Chromosome Aberrations/metabolism , Chromosome Disorders , Chromosomes, Human, Pair 1 , Chromosomes, Human, Pair 16 , Cytosine/metabolism , DNA, Satellite , Female , Humans , Immunologic Deficiency Syndromes/metabolism , Infant , Male , Methylation , Molecular Sequence Data , Syndrome
9.
Infect Immun ; 62(10): 4690-4, 1994 Oct.
Article in English | MEDLINE | ID: mdl-7927744

ABSTRACT

Mycoplasma arginini TUH-14 partially purified membrane lipoproteins (TUH-14-pp) directly induce secretion of the cytokines involved in the inflammatory response, namely, interleukin 1 (IL-1), tumor necrosis factor alpha, and IL-6, by human monocytes cultured in the absence of serum. The biological activity of each cytokine correlates with its immunoreactivity. Upon stimulation with either TUH-14-pp or lipopolysaccharide, most tumor necrosis factor alpha and IL-6 is secreted in the extracellular compartment, whereas a significant amount of IL-1 remains cell associated. Finally, polymyxin B does not affect secretion of cytokines induced by TUH-14-pp, indicating that mycoplasma lipopolysaccharide does not account for their effects on monocytes. Altogether, our data show that direct interaction of mycoplasma membrane components with human blood monocytes induces secretion of high levels of cytokines known to trigger inflammatory responses. This new concept of membrane-bound active components of mycoplasma may explain its ability to efficiently initiate inflammatory reactions.


Subject(s)
Bacterial Proteins/pharmacology , Cytokines/biosynthesis , Lipoproteins/pharmacology , Membrane Proteins/pharmacology , Monocytes/metabolism , Mycoplasma/physiology , Humans , Interleukin-1/biosynthesis , Interleukin-6/biosynthesis , Lipopolysaccharides/pharmacology , Tumor Necrosis Factor-alpha/biosynthesis
10.
Bone Marrow Transplant ; 13(6): 777-82, 1994 Jun.
Article in English | MEDLINE | ID: mdl-7920314

ABSTRACT

Twelve of 15 patients with juvenile chronic myelomonocytic leukemia (JCMML) referred to our unit underwent allogeneic bone marrow transplantation (BMT) between 1982 and 1992. BMT was not performed in the remaining three cases because of poor overall condition in two and disease progression in one. Six patients received marrow from HLA-identical siblings after a chemotherapy conditioning regimen in five cases. BMT failed in one case. Long-term remission was achieved in three patients and two others are in remission 6 and 11 months after BMT. Remission was associated with autologous recovery in one patient and minimal mixed chimerism in another. In one patient, a first BMT procedure resulted in autologous recovery and relapse. A second transplant, with chemotherapy conditioning including TBI, was successful. BMT with marrow from a matched unrelated donor was also successful. IN contrast, BMT with marrow from mismatched related donors (five patients) failed because of graft failure and/or relapse. This single-center series indicates that HLA-identical BMT is an appropriate treatment for JCMML. However, on the basis of these results it cannot be ascertained whether chemotherapy or splenectomy are necessary prior to BMT. The best chemotherapy conditioning regimen remains to be defined, as regimens consisting exclusively of chemotherapy resulted either in long-term remission or in autologous recovery with relapse.


Subject(s)
Bone Marrow Transplantation , Leukemia, Myelomonocytic, Chronic/therapy , Antineoplastic Agents/therapeutic use , Bone Marrow Transplantation/immunology , Child , Child, Preschool , Combined Modality Therapy , Female , France/epidemiology , Histocompatibility/immunology , Humans , Incidence , Infant , Leukemia, Myelomonocytic, Chronic/epidemiology , Male , Tissue Donors , Transplantation, Homologous , Whole-Body Irradiation
11.
Bone Marrow Transplant ; 13(5): 563-9, 1994 May.
Article in English | MEDLINE | ID: mdl-8054909

ABSTRACT

Fifteen children with steroid-resistant acute graft-versus-host disease (GVHD, grade II-IV) were treated with a murine monoclonal antibody (BT 563) specific for the alpha subunit of the interleukin-2 receptor (IL-2R). All had inherited diseases of the bone marrow and had received T cell-depleted marrow from a partially matched related donor. BT 563 antibody was given at a daily dose of 0.2 mg/kg. Treatment was continued until GVHD was controlled and the methylprednisolone administration was tapered to < or = 2 mg/kg/day. No side-effects were noted. Eleven of the 15 patients reached complete remission and a partial remission occurred in two. This good response rate was associated with early treatment (mean time after GVHD onset 7.7 +/- 5.3 days) and prolonged treatment (mean 25.9 +/- 10.6 days) compared with previously published data on BT 563 antibody usage. Relapses occurred in six of the 13 responders but a further remission was induced by the same treatment. Chronic GVHD developed in six cases and one of them died of GVHD-associated infection. Ten of the 15 patients are long-term survivors and are free of chronic GVHD. The results of this pilot study indicate that early and lengthy treatment with anti-IL-2R monoclonal antibody is both safe and effective against steroid-resistant GVHD in young children and indicate that further trials of anti-IL-2R antibody as first-line therapy of acute GVHD are warranted.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Bone Marrow Transplantation/adverse effects , Graft vs Host Disease/therapy , Lymphocyte Depletion , Methylprednisolone/therapeutic use , Receptors, Interleukin-2/immunology , T-Lymphocytes/immunology , Acute Disease , Antibodies, Monoclonal/adverse effects , Child, Preschool , Drug Resistance , Female , Humans , Infant , Male , Pilot Projects
12.
Br J Cancer ; 69(1): 120-4, 1994 Jan.
Article in English | MEDLINE | ID: mdl-8286193

ABSTRACT

Insulin and the insulin-like growth factors (IGFs) may be important regulators of breast cancer growth. The IGF-II receptor is identical to the mannose 6-phosphate (Man-6-P) receptor, which is involved in lysosomal enzyme pathways. In order to determine whether the Man-6-P/IGF-II receptor gene copy number is altered in breast cancer we analysed specimens of invasive breast carcinoma from 51 patients by Southern blotting. No amplification of the receptor gene was observed whatever the clinical presentation of the tumour and irrespective of a concomitant amplification of c-erbB2 or int-2 genes in several tumours. As indicated by Northern blotting, the gene is transcribed in breast tumour tissues and non-tumour breast tissue. These results suggest that the receptor gene is stable in breast carcinoma and that, if anything, the receptor involvement in breast cancer progression may be the result of a disregulation of its expression at a post-transcriptional or post-translational level.


Subject(s)
Breast Neoplasms/genetics , Gene Amplification/genetics , Receptor, IGF Type 2/genetics , Adult , Blotting, Northern , Blotting, Southern , DNA Probes , DNA, Neoplasm/analysis , DNA, Neoplasm/genetics , Female , Humans , Middle Aged , Protein Processing, Post-Translational , Receptor, IGF Type 2/metabolism , Transcription, Genetic/genetics
13.
Clin Exp Rheumatol ; 11(4): 451-6, 1993.
Article in English | MEDLINE | ID: mdl-8403593

ABSTRACT

A macrophage activation syndrome (MAS) developed in four children with chronic rheumatic diseases. The presentation included fever, hepatic and splenic enlargement, profound depression of blood counts, lowering of ESR, elevation of SGOT/PT and hypofibrinogenemia. The most characteristic sign of MAS was the presence in the bone marrow aspirate of well differentiated macrophages showing active haemophagocytosis with haematopoietic elements in their cytoplasm. Activation of the macrophage was also illustrated by high levels of monokines in the serum of 2 patients. This immuno-hematological process of unknown etiology can be triggered by ubiquitous events such as infections and treatment with anti-inflammatory drugs. It is a potentially lethal complication which should be diagnosed rapidly, since administration of high-dose steroids with discontinuation of potentially toxic drugs can induce remission. Cyclosporin A was effective in two patients and may be of value in the management of the macrophage-activation syndrome. Its efficacy supports the central involvement of a T-cell dysfunction. It must be borne in mind that children with rheumatic diseases, especially the systemic form of juvenile chronic arthritis, are highly vulnerable to life-threatening macrophage activation, which appears to be more frequent than previously recognized. Very careful monitoring of apparently "innocent" drugs and intercurrent viral infections is thus required.


Subject(s)
Immune System Diseases/etiology , Macrophage Activation , Rheumatic Diseases/immunology , Adult , Arthritis, Juvenile/complications , Arthritis, Juvenile/immunology , Child , Child, Preschool , Cyclosporine/therapeutic use , Female , Humans , Immune System Diseases/drug therapy , Immune System Diseases/pathology , Liver/pathology , Male , Pancreas/pathology , Rheumatic Diseases/complications , Syndrome
14.
Arch Fr Pediatr ; 49(4): 339-43, 1992 Apr.
Article in French | MEDLINE | ID: mdl-1497422

ABSTRACT

Adenosine deaminase (ADA) deficiency is one the causes of severe combined immunodeficiency syndrome. Treatment was, until now, based on bone marrow transplantation. HLA identical bone marrow transplantation yields excellent results while those of HLA haploidentical bone marrow transplantation are not so good. A new therapeutic approach was developed recently, consisting of the intramuscular infusion of ADA enzyme covalently linked to polyethylene glycol (PEG-ADA). We report the results of this treatment in a 14 month-old child presenting with a partial form of ADA deficiency revealed by an opportunistic infection. This treatment corrected the immunodeficiency and the biochemical abnormalities as well. PEG-ADA infusions were well tolerated. The onset of an immunization against the ADA enzyme led to a drop in immunologic functions, which could be partially overcome by more frequent (biweekly) administration of the product. After a 18 month-follow-up the child is doing well, living normally at home. PEG-ADA represents a possible alternative for children presenting with ADA deficiency without any available HLA identical donor.


Subject(s)
Adenosine Deaminase/administration & dosage , Adenosine Deaminase/deficiency , Polyethylene Glycols/administration & dosage , Severe Combined Immunodeficiency/drug therapy , Adenosine Deaminase/therapeutic use , Drug Combinations , Female , Follow-Up Studies , Humans , Infant , Polyethylene Glycols/therapeutic use , Severe Combined Immunodeficiency/etiology
SELECTION OF CITATIONS
SEARCH DETAIL
...